Determination of pharmacokinetics of flurbiprofen in Pakistani population using modified HPLC method

Journal of Chromatographic Science

Volumn 49, Issue 2, 2011, Pages 108-113

  Qayyum, Aisha ^a   Najmi, Muzammil Hasan ^a   Farooqi, Zia Ur Rehman ^a  

^a NATIONAL UNIVERSITY OF SCIENCES AND TECHNOLOGY   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78751555078     PISSN: 00219665     EISSN: None     Source Type: Journal    
DOI: 10.1093/chrsci/49.2.108     Document Type: Article

References (44)

1. N. A. Charoo, A. A. A. Shamsher, K. Kohli, K. K. Pillai and Z. Rahman. Simple and sensitive high-performance liquid chromatographic method for determination of transdermally applied flurbiprofen in rat plasma and excised skin samples. Chromatographia 62:493-497 (2005).
2. A. E. Good. The pain of ankylosing spondylitis. Am. J. Med. 80:118-119 (1986).
3. D. S. Muckle. Flurbiprofen for the treatment of soft tissue trauma. Am. J. Med. 80:76-80 (1986).
4. H. R. Mena, P. L. Lomen, L. F. Turner, K. R. Lamborn, and E. L. Brinn. Treatment of acute shoulder syndrome with flurbiprofen. Am. J. Med 80:141-144 (1986).
5. S. S. Shapiro. Flurbiprofen for the treatment of primary dysmenorrhea. Am. J. Med. 80:71-75 (1986).
6. P. L. Lomen, B. A. Smal, K. R. Lamborn, L. P. Sattler, and S. L. Crampton. Flurbiprofen for the treatment of bone pain in patients with metastatic breast cancer. Am. J. Med. 80:83-86 (1986).
7. J. A. McIntyre, J. Castaner, and D. Fernandez-Forner. MPC-7869. Drugs Future 31:22 (2006).
8. W. W. Buchanan and Y. B. Kassam. European experience with flurbiprofen - A new analgesic/anti-inflammatory agent. Am. J. Med 80:145-152 (1986).
9. N. M. Davies. Clinical pharmacokinetics of flurbiprofen and its enantiomers. Clin. Pharmacokinet. 28:100-114 (1995).
10. P. C. Risdall, S. S. Adams, E. L. Crampton, and B. Marchant. The disposition and metabolism of flurbiprofen in several species including man. Xenobiotica 8:691-704 (1978).
11. G. J. Szpunar, K. S. Albert, G. G. Bole, J. N. Dreyfus, G. F. Lockwood, and J. G. Wagner. Pharmacokinetics of flurbiprofen in man 1. area/dose relationships. Biopharm. Drug Dispos. 8:273-283 (1987).
12. J. B. Dressman, R. R. Berardi, G. H. Elta, T. M. Gray, P. A. Montgomery, H. S. Lau, K. L. Pelekoudas, G. J. Szpunar, and J. G. Wagner. Absorption of flurbiprofen in the fed and fasted states. Pharm. Res. 9:901-907 (1992).
13. N. K. Zgheib, R. F. Frye, T. S. Tracy, M. Romkes, and R. A. Branch. Evaluation of flurbiprofen urinary ratios as in vivo indices for CYP2C9 activity. Br. J. Clin. Pharmacol. 63:477-487 (2006).
14. F. Jamali, B. W. Berry M. R. Tehrani, and A. S. Russell. Stereoselective pharmacokinetics of flurbiprofen in humans and rats. J. Pharm. Sci. 77:666-669 (1988).
15. T. S. Tracy, B. W. Rosenbluth, S. A. Wrighton, F. J. Gonzalez, and K. R. Korzekwa. Role of cytochrome P450 2C9 and an allelic variant in the 4-hydroxylation of (R) - and (S)-flurbiprofen. Biochem. Pharmacol. 49:1269-1275 (1995).
16. T. S. Tracy, C. Marra, S. A. Wrighton, F. J. Gonzalez, and K. R. Korzekwa. Studies of flurbiprofen 4-hydroxylation Additional evidence suggesting the sole involvement of cytochrome P450 2C9. Biochem. Pharmacol. 52:1305-1309 (1996).
17. M. R. Wester, J. K. Yano, G. A. Schoch, C. Yang, K. J. Griffin, C. D. Stout, and E. F. Johnson. The structure of human cytochrome P450 2C9 complexed with flurbiprofen at 2.0-A resolution. J. Biol. Chem. 279:35630-35637 (2004).
18. S. Dayong, G. Yingjie, Z. Yifan, Y. Lei, Z. Hui, and Z. Dafang. Identification of a novel variant CYP2C9 allele in Chinese. Pharmacogenetics 14:465-469 (2004).
19. G. Suarez-Kurtz. Pharmacogenomics in admixed population. TRENDS Pharmacol. Sci. 26:196-201 (2005).
20. *3 genotypes. Eur. J. Clin. Pharmacol. 58:791-794 (2003).
21. J. Kirchheiner and J. Brockmoller. Clinical consequences of cytochrome P450 2C9 polymorphism. Clin. Pharmacol. Ther. 77:1-16 (2005).
22. M. J. Stubbins, L. W. Harries, G. Smith, M. H. Tarbit, and C. R. Wolf. Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics 6:429-439 (1996).
23. T. H. Sullivan-Klose, B. I. Ghanayem, D. A. Bell, Z. Y. Zhang, L. S. Kaminsky, and G. M. Shenfield. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 6:341-349 (1996).
24. C. R. Bhasker, J. O. Miners, S. Coulter, and D. J. Birkett. Allelic and functional variability of cytochrome P450 CYP2C9. Pharmacogenetics 7:51-58 (1997).
25. G. P. Aithal, C. P. Day, P. J. L. Kesteven, and A. K. Daly. Association of polymorphism in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353:717-719 (1999).
26. J. Van der Weide, L. S. Steijns, M. J. van Weelden, and K. de Haan. The effect of genetic polymorphism in the cytochrome P450 CYP2C9 on phenytoin dose requirement. Pharmacogenetics 11:287-291 (2001).
27. D. J. Kaiser, C. D. Brooks, and P. L. Lomen. Pharmacokinetics of flurbiprofen. Am. J. Med. 80:10-15 (1986).
28. G. Caille, P. du Souich, M. Vezina, S. R. Pollock, and D. J. Stalker. Pharmacokinetic interaction between flurbiprofen and antacids in healthy volunteers. Biopharm. Drug Dispos. 10:607-615 (1989).
29. F. Jamali, D. S. Collins, B. W. Berry, S. Molder, R. Cheung, K. McColl, and H. Cheung. Comparative bioavailability of two flurbiprofen products: stereospecific versus conventional approach. Biopharm. Drug Dispos. 12:435-445 (1991).
30. W. F. Kean, E. J. Antal, E. M. Grace, H. Cauvier, J. Rischke, and W. W. Buchanan. The pharmacokinetics of flurbiprofen in younger and elderly patients with rheumatoid arthritis. J. Clin. Pharmacol. 32:41-48 (1992).
31. A. M. Taburet, E. Singlas, R. C. Glass, F. Thomas and E. Leutenegger. Pharmacokinetic comparison of oral and local action transcutaneous flurbiprofen in healthy volunteers. J. Clin. Pharm. Ther. 20:101-107 (1995).
32. D. J. Greenblatt, L. L. von Moltke, Y. Luo, E. S. Perloff, K. A. Horan, A. Bruce, R. C. Reynolds, J. S. Harmatz, B. Avula, I. A. Khan, and P. Goldman. Ginkgo biloba does not alter clearance of flurbiprofen, a cytochrome P450-2C9 substrate. J. Clin. Pharmacol. 46:214-221 (2006).
33. D. J. Greenblatt, L. L. von Moltke, E. S. Perloff, Y. Luo, J. S. Harmatz, and M. A. Zinny. Interaction of flurbiprofen with cranberry juice, grape juice, tea and fluconazole: In vitro and clinical studies. Clin. Pharmacol. Ther. 79:125-133 (2006).
34. V. V. Dhavse, D. V. Parmar, and P. V. Devarajan. High-performance thin-layer chromatographic determination of flurbiprofen in plasma. J. Chromatogr. B: Biomed. Sci. Appl. 694:449-453 (1997).
35. C. Scaroni, PL. Mazzoni, E. D'Amico, C. Benvenuti, and I. D. Hind. Pharmacokinetics of oral and rectal flurbiprofen in children. Eur. J. Clin. Pharmacol. 27:367-369 (1984).
36. K. S. Albert, W. R. Gillespie, A. Raabe, and M. Garry. Determination of flurbiprofen in human serum by reverse-phase high-performance liquid chromatograpy with fluorescence detection. J. Pharm. Sci. 73:1823-1825 (1984).
37. V. A. Johnson and J. T. Wilson. Flurbiprofen analysis in plasma and breast milk by high-performance liquid chromatograpy. J. Chromatogr. 382:367-371 (1986).
38. W. J. Adams, B. E. Bothwell, G. J. Van Giessen, and D. G. Kaiser. Simultaneous determination of flurbiprofen and its major metabolites in physiological fluids using liquid chromatography with fluorescence detection. Anal. Chem. 59:1504-1509 (1987).
39. M. P. Knadler and S. D. Hall. High-performance liquid chromatographic analysis of the enantiomers of flurbiprofen and its metabolites in plasma and urine. J. Chromatogr. 494:173-182 (1989).
40. M. C. Jerdi, Y. Daali, M. K. Oestreicher, S. Cherkaoui, and P. Dayer. A simplified analytical method for a phenotyping cocktail of major CYP450 biotransformation routes. J. Pharm. Biomed. Anal. 35:1203-1212 (2004).
41. J. M. Hutzler, R. F. Frye, and T. S. Tracy. Sensitive and specific highperformance liquid chromatographic assay for 4'-hydroxyflurbiprofen and flurbiprofen in human urine and plasma. J. Chromatogr. B: Biomed. Sci. Appl. 749:119-125 (2000).
42. ICH Harmonized Tripartite Guideline. International conference on harmonization of technical requirements for registration of pharmaceuticals for human use. Validation of analytical procedures: Text and methodology (2005).
43. FDA Guidance for industry. E6 Good Clinical Practice: Consolidated Guidance. U. S. Department of Health and Human Services. Food and Drug Administration, Centerfor Drug Evaluation and Research (1996).
44. World Medical Association Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects. Adopted by the 18th WMA General Assembly (1964) Helsinki, Finland and amended by the 52nd WMA General Assembly (2000) Edinburgh, Scotland.